Advanced search
Publication Cover
Journal of Asthma Volume 49, 2012 - Issue 4
Submit an article Journal homepage
1,128
Views
65
CrossRef citations to date
0
Altmetric
Pharmacotherapy

Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches

María Del Carmen VenneraDepartment of Pneumology and Respiratory Allergy, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain;Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Palma de Mallorca, SpainCorrespondence[email protected] [email protected]
, M.D.,
Luis Pérez De LlanoDepartment of Pneumology, Hospital Xeral-Calde, Rua Doutor Ochoa, Lugo, Spain
, M.D., Ph.D.,
Santiago BardagíDepartment of Pneumology, Hospital General de Mataró, Mataró, Spain
, M.D.,
Pilar AusinCentro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Palma de Mallorca, Spain;Department of Pneumology, Hospital del Mar-IMIM, Barcelona, Spain
, M.D.,
Carles SanjuasCentro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Palma de Mallorca, Spain;Department of Pneumology, Hospital del Mar-IMIM, Barcelona, Spain
, M.D., Ph.D.,
Héctor GonzálezDepartment of Pneumology, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain
, M.D., Ph.D.,
José A. GullónDepartment of Pneumology, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain
, M.D., Ph.D.,
Eva Martínez-MoragónDepartment of Pneumology, Hospital de Sagunto, Valencia, Spain
, M.D., Ph.D.,
José A. CarreteroDepartment of Pneumology, Hospital Universitario M. Servet, Zaragoza, Spain
, M.D., Ph.D.,
Elisabet VeraDepartment of Pneumology, Hospital Universitario M. Servet, Zaragoza, Spain
, M.D.,
Juan F. MedinaDepartment of Pneumology, Hospital Universitario V. del Rocío, Sevilla, Spain
, M.D.,
Francisco J. ÁlvarezDepartment of Pneumology, Hospital Universitario V. del Rocío, Sevilla, Spain
, M.D.,
Luis M. EntrenasDepartment of Pneumology, Hospital Universitario Reina Sofía, Córdoba, Spain
, M.D., Ph.D.,
Alicia PadillaDepartment of Pneumology, Hospital Costa del Sol, Marbella, Spain
, M.D.,
Rosa IrigarayDepartment of Pneumology, Hospital de Manacor, Manacor, Spain
, M.D.,
César PicadoDepartment of Pneumology and Respiratory Allergy, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain;Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Palma de Mallorca, Spain
, M.D., Ph.D. & on behalf of the Spanish Registry show all
Pages 416-422 | Published online: 23 Mar 2012

Citations (65)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (13)

Santiago Quirce, Carlos Melero, Alicia Huerta, Estefany Uría & Maribel Cuesta. (2021) Economic impact of severe asthma exacerbations in Spain: multicentre observational study. Journal of Asthma 58:2, pages 207-212.
Read now
Kenneth M. Faulkner, Karen MacDonald, Ivo Abraham, Abdulaziz Alhossan & Christopher S. Lee. (2021) ‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Review of Clinical Immunology 17:1, pages 73-83.
Read now
Jason K Lee, Suvina Amin, Michelle Erdmann, Atif Kukaswadia, Jelena Ivanovic, Aren Fischer & Alain Gendron. (2020) Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada. Patient Preference and Adherence 14, pages 725-735.
Read now
Aleksandra Kucharczyk, Ewa Więsik-Szewczyk, Anna Poznańska & Karina Jahnz-Różyk. (2020) Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation. Journal of Asthma and Allergy 13, pages 659-668.
Read now
Marco Caminati, Brooke Polk & Lanny J. Rosenwasser. (2019) What have recent advances in therapy taught us about severe asthma disease mechanisms?. Expert Review of Clinical Immunology 15:11, pages 1145-1153.
Read now
Carlos Melero Moreno, Santiago Quirce, Alicia Huerta, Estefany Uría & Maribel Cuesta. (2019) Economic impact of severe asthma in Spain: multicentre observational longitudinal study. Journal of Asthma 56:8, pages 861-871.
Read now
Karen M. MacDonald, Abhishek Kavati, Benjamin Ortiz, Abdulaziz Alhossan, Christopher S. Lee & Ivo Abraham. (2019) Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology 15:5, pages 553-569.
Read now
Stephanie Chen, Sarowar Golam, Julie Myers, Chris Bly, Harry Smolen & Xiao Xu. (2018) Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Current Medical Research and Opinion 34:12, pages 2075-2088.
Read now
Maxime Luu, Marc Bardou, Philippe Bonniaud & Françoise Goirand. (2016) Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1503-1511.
Read now
Evgenia Papathanassiou, Stelios Loukides & Petros Bakakos. (2016) Severe asthma: anti-IgE or anti-IL-5?. European Clinical Respiratory Journal 3:1.
Read now
María del Carmen Vennera & César Picado. (2014) Novel diagnostic approaches and biological therapeutics for intrinsic asthma. International Journal of General Medicine 7, pages 365-371.
Read now
Eylem Sercan Özgür, Cengiz Özge, Ahmet Ïlvan & Sibel Atış Naycı. (2013) Assessment of Long-term Omalizumab Treatment in Patients with Severe Allergic Asthma Long-term Omalizumab Treatment in Severe Asthma. Journal of Asthma 50:6, pages 687-694.
Read now
Neil Barnes, Andrew Menzies-Gow, Adel H. Mansur, David Spencer, Fran Percival, Amr Radwan & Rob Niven. (2013) Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study. Journal of Asthma 50:5, pages 529-536.
Read now

Articles from other publishers (52)

V. V. Naumova, E. K. Beltyukov, D. V. Kiseleva, A. A. Shtanova & D. A. Stepina. (2023) Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract. Meditsinskiy sovet = Medical Council:20, pages 68-83.
Crossref
Schneider K.O., Maksimov M.L., Romanov B.K., Gusarova O.A. & Baranova V.A.. (2023) USE OF HUMANIZED OFF-LABEL MONOCLONAL ANTIBODIES IN PEDIATRIC PRACTICE. Bulletin "Biomedicine and sociology", pages 17-32.
Crossref
C. Cisneros-Serrano, M.J. Rial, A. Gómez-Bastero-Fernández, J.M. Igea, A. Martínez-Meca, L.C. Fernández-Lisón, V. López-Carrasco, E. Villamañán-Bueno, M.J. Plá-Martí & E. Chiner. (2023) Spanish multidisciplinary consensus on the characteristics of severe asthma patients on biologic treatment who are candidates for at-home administration. Revista Clínica Española (English Edition) 223:3, pages 154-164.
Crossref
C. Cisneros-Serrano, M.J. Rial, A. Gómez-Bastero-Fernández, J.M. Igea, A. Martínez-Meca, L.C. Fernández-Lisón, V. López-Carrasco, E. Villamañán-Bueno, M.J. Plá-Martí & E. Chiner. (2023) Consenso multidisciplinar español sobre las características de los pacientes con asma grave en tratamiento con biológicos susceptibles de pasar a tratamiento domiciliario. Revista Clínica Española 223:3, pages 154-164.
Crossref
Diego Bagnasco, Rikki Frank Canevari, Stefano Del Giacco, Silvia Ferrucci, Paolo Pigatto, Paolo Castelnuovo, Gian Luigi Marseglia, Arzu Didem Yalcin, Girolamo Pelaia & Giorgio Walter Canonica. (2022) Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps. World Allergy Organization Journal 15:12, pages 100721.
Crossref
Nicola A. Hanania, Robert Niven, Pascal Chanez, Deschildre Antoine, Pascal Pfister, Lorena Garcia Conde & Xavier Jaumont. (2022) Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organization Journal 15:10, pages 100695.
Crossref
Mona Al Ahmad, Lilia Margarita Borboa Olivares, Alexandre Pinto Cardoso, Wagih Djazmati, Miguel Angel Vinuesa, María de Jesús García Domínguez, Alcindo Cerci Neto, Luis Ugalde Gamboa, Jason K. Lee, Nadine Pinho & Paolo Tassinari. (2022) Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study. The Open Respiratory Medicine Journal 16:1.
Crossref
Francisco Javier Alvarez-Gutiérrez, Marina Blanco-Aparicio, Francisco Casas-Maldonado, Vicente Plaza, Francisco Javier González-Barcala, José Ángel Carretero-Gracia, Manuel Castilla-Martínez, Carolina Cisneros, David Diaz-Pérez, Christian Domingo-Ribas, Eva Martínez-Moragon, Xavier Muñoz, Alicia Padilla-Galo, Miguel Perpiñá-Tordera & Gregorio Soto-Campos. (2022) Documento de consenso de asma grave en adultos. Actualización 2022. Open Respiratory Archives 4:3, pages 100192.
Crossref
Giovanni Paoletti, Jack Pepys, Marta Casini, Danilo Di Bona, Enrico Heffler, Celine Y.Y. Goh, David B. Price & Giorgio Walter Canonica. (2022) Biologics in severe asthma: the role of real-world evidence from registries. European Respiratory Review 31:164, pages 210278.
Crossref
Roberto Bernardini, Gaia Toschi Vespasiani & Arianna Giannetti. (2022) An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics. Medicina 58:5, pages 625.
Crossref
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta & Konstantinos Porpodis. (2022) Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine 12:2, pages 165.
Crossref
Alexandrosz Czira, Monica Turner, Amber Martin, David Hinds, Helen Birch, Frances Gardiner & Shiyuan Zhang. (2022) A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma. Respiratory Medicine 191, pages 106670.
Crossref
Jean Bousquet, Marc Humbert, Peter G. Gibson, Konstantinos Kostikas, Xavier Jaumont, Pascal Pfister & Francis Nissen. (2021) Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology: In Practice 9:7, pages 2702-2714.
Crossref
J. Mark FitzGerald, Trung N. Tran, Marianna Alacqua, Alan Altraja, Vibeke Backer, Leif Bjermer, Unnur Bjornsdottir, Arnaud Bourdin, Guy Brusselle, Lakmini Bulathsinhala, John Busby, Giorgio W. Canonica, Victoria Carter, Isha Chaudhry, You Sook Cho, George Christoff, Borja G. Cosio, Richard W. Costello, Neva Eleangovan, Peter G. Gibson, Liam G. Heaney, Enrico Heffler, Mark Hew, Naeimeh Hosseini, Takashi Iwanaga, David J. Jackson, Rupert Jones, Mariko S. Koh, Thao Le, Lauri Lehtimäki, Dora Ludviksdottir, Anke H. Maitland-van der Zee, Andrew Menzies-Gow, Ruth B. Murray, Nikolaos G. Papadopoulos, Luis Perez-de-Llano, Matthew Peters, Paul E. Pfeffer, Todor A. Popov, Celeste M. Porsbjerg, Chris A. Price, Chin K. Rhee, Mohsen Sadatsafavi, Yuji Tohda, Eileen Wang, Michael E. Wechsler, James Zangrilli & David B. Price. (2020) International severe asthma registry (ISAR): protocol for a global registry. BMC Medical Research Methodology 20:1.
Crossref
Francisco Javier Álvarez-Gutiérrez, Marina Blanco-Aparicio, Vicente Plaza, Carolina Cisneros, Juan Luis García-Rivero, Alicia Padilla, Luis Pérez-de Llano, Miguel Perpiñá & Gregorio Soto-Campos. (2020) Documento de consenso de asma grave en adultos. Actualización 2020. Open Respiratory Archives 2:3, pages 158-174.
Crossref
Eileen Wang, Michael E. Wechsler, Trung N. Tran, Liam G. Heaney, Rupert C. Jones, Andrew N. Menzies-Gow, John Busby, David J. Jackson, Paul E. Pfeffer, Chin Kook Rhee, You Sook Cho, G. Walter Canonica, Enrico Heffler, Peter G. Gibson, Mark Hew, Matthew Peters, Erin S. Harvey, Marianna Alacqua, James Zangrilli, Lakmini Bulathsinhala, Victoria A. Carter, Isha Chaudhry, Neva Eleangovan, Naeimeh Hosseini, Ruth B. Murray & David B. Price. (2020) Characterization of Severe Asthma Worldwide. Chest 157:4, pages 790-804.
Crossref
Luis A. Pérez de Llano, Borja G. Cosío, Christian Domingo, Isabel Urrutia, Irina Bobolea, Antonio Valero, Luis M. Entrenas Costa, Santiago Quirce, Pilar Barranco, Nuria Marina Malanda, Luis Prieto Andrés & Francisco J. Alvarez-Gutiérrez. (2019) Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. The Journal of Allergy and Clinical Immunology: In Practice 7:7, pages 2277-2283.e2.
Crossref
Luis Manuel Entrenas Costa, Francisco Casas-Maldonado, José Gregorio Soto Campos, Alicia Padilla-Galo, Alberto Levy, Francisco Javier Álvarez Gutiérrez, Ana P. Gómez-Bastero Fernández, Concepción Morales-García, Rocío Gallego Domínguez, Gustavo Villegas Sánchez, Luis Mateos Caballero, Antonio Pereira-Vega, Cayo García Polo, Gerardo Pérez Chica & Juan José Martín Villasclaras. (2019) Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. PharmacoEconomics - Open 3:3, pages 333-342.
Crossref
Gilda Varricchi, Giancarlo Marone, Giuseppe Spadaro, Michele Russo, Francescopaolo Granata, Arturo Genovese & Gianni Marone. (2019) Novel Biological Therapies in Severe Asthma: Targeting the Right Trait. Current Medicinal Chemistry 26:16, pages 2801-2822.
Crossref
Enrico Heffler, Francesco Blasi, Manuela Latorre, Francesco Menzella, Pierluigi Paggiaro, Girolamo Pelaia, Gianenrico Senna, Giorgio Walter Canonica, Sarah Barbuto, Matteo Bradicich, Gianna Camiciottoli, Marco Caminati, Giselda Colombo, Maria Teresa Costantino, Nunzio Crimi, Mariangiola Crivellaro, Alice D’Adda, Mariella D’Amato, Elisabetta Favero, Maria Pia Foschino, Carla Galeone, Gabriella Guarnieri, Carlo Lombardi, Roberta Parente, Giovanni Passalacqua, Vincenzo Patella, Francesca Puggioni, Erminia Ridolo, Giovanni Rolla, Eleonora Savi, Nicola Scichilone, Paolo Solidoro & Giuseppe Spadaro. (2019) The Severe Asthma Network in Italy: Findings and Perspectives. The Journal of Allergy and Clinical Immunology: In Practice 7:5, pages 1462-1468.
Crossref
Joanna Chorostowska-Wynimko, Marion Wencker & Ildikó Horváth. (2019) The importance of effective registries in pulmonary diseases and how to optimize their output. Chronic Respiratory Disease 16, pages 147997311988177.
Crossref
Ana Sá-Sousa, João Almeida Fonseca, Ana Margarida Pereira, Ana Ferreira, Ana Arrobas, Ana Mendes, Marta Drummond, Wanda Videira, Tiago Costa, Pedro Farinha, José Soares, Pedro Rocha, Ana Todo-Bom, Anna Sokolova, António Costa, Beatriz Fernandes, Carla Chaves Loureiro, Cecília Longo, Cecília Pardal, Célia Costa, Cíntia Cruz, Cláudia Chaves Loureiro, Cristina Lopes, Duarte Mesquita, Emília Faria, Eunice Magalhães, Fernando Menezes, Filipa Todo-Bom, Francisca Carvalho, Frederico S. Regateiro, Helena Falcão, Ivone Fernandes, João Gaspar-Marques, Jorge Viana, José Ferreira, José Manuel Silva, Laura Simão, Leonor Almeida, Lígia Fernandes, Lurdes Ferreira, Mafalda van Zeller, Márcia Quaresma, Margarida Castanho, Natália André, Nuno Cortesão, Paula Leiria-Pinto, Paula Pinto, Paula Rosa, Pedro Carreiro-Martins, Rita Gerardo, Rui Silva, Susana Lucas, Teresa Almeida & Teresa Calvo. (2018) The Portuguese Severe Asthma Registry: Development, Features, and Data Sharing Policies. BioMed Research International 2018, pages 1-12.
Crossref
Maria del Carmen Vennera, Carlos Sabadell & Cesar Picado. (2018) Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma. Thorax 73:8, pages 782-784.
Crossref
Christian Domingo, Xavier Pomares, Albert Navarro, María José Amengual, Concepción Montón, Ana Sogo & Rosa M. Mirapeix. (2018) A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients. British Journal of Clinical Pharmacology 84:2, pages 339-348.
Crossref
Giorgio Walter Canonica, Paola Rottoli, Caterina Bucca, Maria Cristina Zappa, Giovanni Michetti, Bruno Macciocchi, Cristiano Caruso, Pierachille Santus, Marta Bartezaghi & Laura Rigoni. (2018) Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. World Allergy Organization Journal 11, pages 33.
Crossref
Eleftherios Zervas, Konstantinos Samitas, Andriana I. Papaioannou, Petros Bakakos, Stelios Loukides & Mina Gaga. (2018) An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Research 4:1, pages 00125-2017.
Crossref
Arzu Yorgancıoğlu, Ferda Öner Erkekol, Dilşad Mungan, Münevver Erdinç, Bilun Gemicioğlu, Zeynep Ferhan Özşeker, Papatya Bayrak Değirmenci , Sibel Naycı, Aykut Çilli, Füsun Erdenen, Cengiz Kırmaz, Dane Ediger, Arzu Didem Yalçın, Suna Büyüköztürk, Sami Öztürk, Mustafa Güleç, Sacide Rana Işık, Ali Fuat Kalyoncu, Özlem Göksel, Ömür Aydın, Yavuz Havlucu, İdilhan Baloğlu Ar & Ahmet Erdoğdu. (2018) Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial. International Archives of Allergy and Immunology 176:3-4, pages 225-233.
Crossref
Mina Tadrous, Wayne Khuu, Gerald Lebovic, Matthew B. Stanbrook, Diana Martins, J. Michael Paterson, Muhammad M. Mamdani, David N. Juurlink & Tara Gomes. (2018) Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. Annals of Allergy, Asthma & Immunology 120:1, pages 59-65.e2.
Crossref
G. Senna, M. Guerriero, P. L. Paggiaro, F. Blasi, M. Caminati, E. Heffler, M. Latorre & G. W. Canonica. (2017) SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma. Clinical and Molecular Allergy 15:1.
Crossref
F. Paganin, G. Mangiapan, A. Proust, A. Prudhomme, J. Attia, S. Marchand-Adam, F. Pellet, F. Milhe, B. Melloni, A. Bernady, C. Raspaud, C. Nocent, P. Berger & L. Guilleminault. (2017) Lung function parameters in omalizumab responder patients: An interesting tool?. Allergy 72:12, pages 1953-1961.
Crossref
Christian Domingo. (2017) Overlapping Effects of New Monoclonal Antibodies for Severe Asthma. Drugs 77:16, pages 1769-1787.
Crossref
Danilo Di Bona, Irene Fiorino, Marialuisa Taurino, Flavia Frisenda, Elena Minenna, Carlo Pasculli, Georgios Kourtis, Anna Simona Rucco, Andrea Nico, Marcello Albanesi, Lucia Giliberti, Luciana D'Elia, Maria Filomena Caiaffa & Luigi Macchia. (2017) Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respiratory Medicine 130, pages 55-60.
Crossref
Abdulaziz Alhossan, Christopher S. Lee, Karen MacDonald & Ivo Abraham. (2017) “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice 5:5, pages 1362-1370.e2.
Crossref
Bruno Sposato, Marco Scalese, Manuela Latorre, Federica Novelli, Nicola Scichilone, Manlio Milanese, Carmela Olivieri, Antonio Perrella & Pierluigi Paggiaro. (2017) Can the response to Omalizumab be influenced by treatment duration? A real-life study. Pulmonary Pharmacology & Therapeutics 44, pages 38-45.
Crossref
Christian Domingo, Xavier Pomares, Albert Navarro, Núria Rudi, Ana Sogo, Ignacio Dávila & Rosa Mirapeix. (2017) Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study. International Journal of Molecular Sciences 18:3, pages 521.
Crossref
M. Caminati, G. Senna, G. Stefanizzi, R. Bellamoli, S. Longhi, F. Chieco-Bianchi, G. Guarnieri, S. Tognella, M. Olivieri, C. Micheletto, G. Festi, E. Bertocco, M. Mazza, A. Rossi & A. Vianello. (2016) Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulmonary Medicine 16:1.
Crossref
Izabela Kupryś-Lipińska, Paweł Majak, Joanna Molinska & Piotr Kuna. (2016) Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulmonary Medicine 16:1.
Crossref
Aleksandra Chudzicka, Renata Rożyńska & Adam Wesołowski. (2016) Radykalna poprawa kontroli astmy oskrzelowej po włączeniu do leczenia omalizumabu – opis przypadku. Alergologia Polska - Polish Journal of Allergology 3, pages S10-S13.
Crossref
María del Carmen Vennera, Antonio Valero, Estefany Uría, Carles Forné & César Picado. (2016) Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical Drug Investigation 36:7, pages 567-578.
Crossref
I. Abraham, A. Alhossan, C. S. Lee, H. Kutbi & K. MacDonald. (2016) ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 71:5, pages 593-610.
Crossref
Giorgio Walter Canonica, Marta Bartezaghi, Raffaele Marino & Laura Rigoni. (2015) Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient reported outcomes study. Clinical and Molecular Allergy 13:1.
Crossref
Luis Alejandro Pérez de Llano, Juan Luis García Rivero, Abel Pallares, Noemí Mengual & Rafael Golpe. (2015) Asma corticodependiente: nuestra experiencia clínica. Archivos de Bronconeumología 51:12, pages 660-661.
Crossref
Luis Alejandro Pérez de Llano, Juan Luis García Rivero, Abel Pallares, Noemí Mengual & Rafael Golpe. (2015) Cortico-dependent Asthma: Our Clinical Experience. Archivos de Bronconeumología (English Edition) 51:12, pages 660-661.
Crossref
A.S. Sousa, A.M. Pereira, J.A. Fonseca, L.F. Azevedo, C. Abreu, A. Arrobas, T. Calvo, M.J. Silvestre, L. Cunha, H. Falcão, M. Drummond, L. Geraldes & C. Loureiro. (2015) Asthma control and exacerbations in patients with severe asthma treated with omalizumab in Portugal. Revista Portuguesa de Pneumologia (English Edition) 21:6, pages 327-333.
Crossref
Marco Caminati, Gianenrico Senna, Massimo Guerriero, Anna Rita Dama, Fulvia Chieco-Bianchi, Giorgia Stefanizzi, Marcello Montagni & Erminia Ridolo. (2015) Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address. Pulmonary Pharmacology & Therapeutics 31, pages 28-35.
Crossref
Arzu Didem Yalcin. (2015) Advances in Anti-IgE Therapy. BioMed Research International 2015, pages 1-11.
Crossref
AD Yalcin. (2014) ANTI-Ige: An Overview. Global Journal of Allergy, pages 003-012.
Crossref
Marco Caminati, Gianenrico Senna, Fulvia Chieco Bianchi, Maria Rita Marchi, Andrea Vianello, Claudio Micheletto, Carlo Pomari, Silvia Tognella, Francesca Savoia, Valentina Mirisola & Andrea Rossi. (2014) Omalizumab management beyond clinical trials: The added value of a network model. Pulmonary Pharmacology & Therapeutics 29:1, pages 74-79.
Crossref
Javier de Miguel-Díez, Rodrigo Jiménez-García, Valentín Hernández-Barrera, Ana López de Andrés, José Ramón Villa-Asensi, Vicente Plaza & Pilar Carrasco-Garrido. (2014) National trends in hospital admissions for asthma exacerbations among pediatric and young adult population in Spain (2002–2010). Respiratory Medicine 108:7, pages 983-991.
Crossref
G.-J. Braunstahl, C.-W. Chen, R. Maykut, P. Georgiou, G. Peachey & J. Bruce. (2013) The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma. Respiratory Medicine 107:8, pages 1141-1151.
Crossref
Diego Jose Maselli, Harjinder Singh, Joseph Diaz & Jay I. Peters. (2013) Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study. Annals of Allergy, Asthma & Immunology 110:6, pages 457-461.
Crossref
María del Carmen Vennera & César Picado. (2012) Patologías mediadas por la inmunoglobulina E: de la inmunoglobulina E al omalizumab. Inmunología 31:4, pages 119-126.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.